Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIGGER
NCT02676089Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in asthma (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second at 52 weeks and Moderate and Severe Asthma Exacerbation Rate at 52 weeks. Started Apr 2016; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02676089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676089.